AdAlta
next generation protein therapeutics

ASX Announcement

AdAlta announces additional, positive safety data of AD-114 in non-human primates

MELBOURNE Australia, 19th September, 2017: AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, is pleased to announce the results of its third pre-clinical, safety study in non-human primates, to support the package of preclinical information required by potential pharmaceutical partners.

The ascending, repeat-dose study examined the safety and pharmacokinetic activity of AdAlta's lead program, AD-114, when delivered daily for a period of seven days through subcutaneous and intravenous routes at multiple dose levels.

Dosing was well tolerated at each of the levels with no study mortalities or adverse effects relating to AD-114.

AdAlta's Managing Director & CEO, Sam Cobb commented, "We were very pleased with the way that AD-114 performed in our third non-human primate study. It appears to be safe and well tolerated and the fact that no off-target effects were observed helps to build the case for AD-114 as a potential therapy for fibrosis.

"We are now preparing to run the four week non-human primate toxicology study in the first half of 2018; with this being the last hurdle before AD-114 enters human clinical trials in 2018."

AdAlta Limited
15/2 Park Drive
Bundoora VIC 3083 Australia

T +61 3 9479 5159
E enquiries@adalta.com.au
ABN 92 120 332 925

adalta.com.au

Notes to Editors

About AdAlta

AdAlta Limited is an Australian based drug development company headquartered in Melbourne. The Company is focused on using its proprietary technology platform to generate i-bodies, a new class of protein therapeutics, with applications as therapeutic drugs to treat disease.

I-bodies are a promising, novel class of drugs that offer a new and more effective approach to treating a wide range of human diseases. They are identified and developed using our proprietary technology platform.

We have pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, that was discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, now known as i-bodies, for use in treating serious diseases.

AdAlta is developing its lead i-body candidate, AD-114, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need.

The Company also plans to continue further drug discovery and development directed towards other drug targets and diseases with its i-body technology platform.

Further information can be found at: www.adalta.com.au.

For more information, please contact:

AdAlta Limited
Sam Cobb, CEO
Tel: +61 (0)3 9479 5159
E: s.cobb@adalta.com.au